Advanced search
Publication Cover
Future Medicinal Chemistry Volume 6, 2014 - Issue 4
Submit an article Journal homepage
115
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Synthesis, Pharmacological Study and Docking Calculations of New Benzo[f]coumarin Derivatives as Dual Inhibitors of Enzymatic Systems Involved in Neurodegenerative Diseases

Maria João Matos2 CIQUP/Department of Chemistry & Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal;1 Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, SpainCorrespondence[email protected]
View further author information
,
Patricia Janeiro1 Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, SpainView further author information
,
Rosa María González Franco3 Department of Pharmacology, Center for Research in Molecular Medicine & Chronic Disease, University of Santiago de Compostela, 15782Santiago de Compostela, SpainView further author information
,
Santiago Vilar4 Department of Biomedical Informatics, Columbia University Medical Center, New York, NY10032, USAView further author information
,
Nicholas P Tatonetti4 Department of Biomedical Informatics, Columbia University Medical Center, New York, NY10032, USAView further author information
,
Lourdes Santana1 Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, SpainView further author information
,
Eugenio Uriarte1 Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, SpainView further author information
,
Fernanda Borges2 CIQUP/Department of Chemistry & Biochemistry, Faculty of Sciences, University of Porto, Porto, PortugalView further author information
,
José Angel Fontenla5 Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, SpainView further author information
&
Dolores Viña3 Department of Pharmacology, Center for Research in Molecular Medicine & Chronic Disease, University of Santiago de Compostela, 15782Santiago de Compostela, SpainView further author information
 show all
Pages 371-383 | Published online: 17 Mar 2014

References

  • Castellani RJ , RolstonRK, SmithMA. Alzheimer disease.Dis. Mon.56, 484–546 (2010).
  • Nelson PT , AlafuzoffI, BigioEHet al. Correlation of alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362–381 (2012).
  • Khairallah MI , KassemLA. Alzheimer’s disease: current status of etiopathogenesis and therapeutic strategies.Pak. J. Biol. Sci.14, 257–272 (2011).
  • Farlow MR , CummingsJL. Effective pharmacologic management of Alzheimer’s disease.Am. J. Med.120, 388–397 (2007).
  • Turner PR , O‘ConnorK, TateWPet al. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol. 70, 1–32 (2003).
  • Priller C , BauerT, MittereggerGet al. Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 26, 7212–7221 (2006).
  • Talesa VM . Acethylcholinesterase in Alzheimer’s disease.Mech. Ageing Dev.122, 1961–1969 (2001).
  • García-Alloza M , Gil-BeaFJ, Díez-ArizaMet al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer´s disease. Neurophysychologia 442–449 (2005).
  • Terry AV , BuccafuscoJJ, WilsonC. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.Behav. Brain Res.195, 30–38 (2008).
  • Perry EK , PerryRH, BlessedG. Changes in brain cholinesterases in senile dementia of Alzheimer´s type.Neuropathol. Appl. Neurobiol.4, 273–277 (1978).
  • Weinstock M , GorodetskyE, PoltyrevTet al. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment o dementia comorbid with depression and Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 555–561 (2003).
  • Lane RM , PotkinSG, EnzA. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.Int. J. Neuropsychopharmacol.9, 101–124 (2006).
  • Soukup O , JunD, Zdarova-KarasovaJet al. A resurrection of 7-MEOTA: a comparison with tacrine. Curr. Alzheimer Res. 10, 893–906 (2013).
  • Scarpini E , ScheltensP, FeldmanH. Treatment of Alzheimer’s disease: current status and new perspectives.Lancet Neurol.2, 539–547 (2003).
  • Geldmacher DS . Treatment guidelines for Alzheimer´s disease: redefining perceptions in primary care.Prim. Care Companion J. Clin. Psychiatry9, 113–121 (2007).
  • Bekris LM , MataIF, ZabetianCP. The genetics of Parkinson disease.J. Geriatr. Psychiatry Neurol.23, 228–242 (2010).
  • Youdim MBH . Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson´s and Alzheimer´s disorders?RMMJ.1, 1–18 (2010).
  • Singh N , PillayV, ChoonaraYE. Advances in the treatment of Parkinson’s disease.Prog. Neurobiol.81, 29–44 (2007).
  • Schapira AH , JennerP. Etiology and pathogenesis of Parkinson’s disease.Mov. Disord.26, 1049–1055 (2011).
  • Schapira AH . Aetiopathogenesis of Parkinson’s disease.J. Neurol.258, S307–S310 (2011).
  • Gao HM , HongJS. Gene-environment interactions: key to unraveling the mystery of Parkinson’s disease.Prog. Neurobiol.94, 1–19 (2011).
  • Hindle JV . Ageing, neurodegeneration and Parkinson’s disease.Age Ageing.39, 156–161 (2010).
  • Schulz JB . Update on the pathogenesis of Parkinson’s disease.J. Neurol.255, S3–S7 (2008).
  • Tanner CM . Advances in environmental epidemiology.Mov. Disord.25, S58–S62 (2010).
  • Lai BC , MarionSA, TeschkeKet al. Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat. Disord. 8, 297–309 (2002).
  • Youdim MB , BakhleYS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness.Br. J. Pharmacol.147, S287–S296 (2006).
  • Sano M , ErnestoC, ThomasRGet al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. New Eng. J. Med. 336, 1216–1222 (1997).
  • Youdim MBH , WadiaJS, TattonWG. Neuroprotective properties of the antiparkinson drug rasagiline and its optical S-isomer.Neurosci. Letts. Suppl.54, S45 (1999).
  • Tatton WG , Chalmers-RedmanRME. Modulation of gene expression rather than monoamine oxidase inhibition: R(-)-deprenyl-related compounds in controlling neurodegeneration. Neurology47, S171–S183 (1996).
  • Cavalli A , BolognesiML, MinariniAet al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51, 347–372 (2008).
  • Yáñez M , ViñaD. Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease.Curr. Top. Med. Chem.13, 1692–1706 (2013).
  • Matos MJ , ViñaD, Vázquez-RodríguezSet al. Focusing on new monoamine oxidase inhibitors: differently substituted coumarins as an interesting scaffold. Curr. Top. Med. Chem. 12, 2210–2239 (2012).
  • Hoerr R , NoeldnerM. Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment.CNS Drug Rev.8, 143–158 (2002).
  • Bruhlmann C , OomsF, CarruptPAet al. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem. 44, 3195–3198 (2001).
  • Anand P , SinghB, SinghN. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer’s disease.Bioorg. Med. Chem.20, 1175–1180 (2012).
  • Viña D , MatosMJ, YáñezMet al. 3-substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer´s disease. Med. Chem. Comm. 3, 213–218 (2012).
  • Yáñez M , FraizN, CanoEet al. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. Res. Commun. 344, 688–695 (2006).
  • Maestro, version 9.2, Schrödinger, LLC, New York, NY (2011).
  • Glide, version 5.7, Schrödinger, LLC, New York, NY (2011).
  • LigPrep, version 2.5, Schrödinger, LLC, New York, NY (2011).
  • Prime, version 3.0, Schrödinger, LLC, New York, NY (2011).
  • Matos MJ , ViñaD, PicciauCet al. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett. 19, 5053–5055 (2009).
  • Matos MJ , ViñaD, QuezadaEet al. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett. 19, 3268–3270 (2009).
  • Matos MJ , TeránC, Pérez-CastilloYet al. Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J. Med. Chem. 54, 7127–7137 (2011).
  • Matos MJ , ViñaD, JaneiroPet al. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett. 20, 5157–5160 (2010).
  • Matos MJ , Vázquez-RodríguezS, UriarteEet al. MAO inhibitory activity modulation: 3-phenylcoumarins versus 3-benzoylcoumarins. Bioorg. Med. Chem. Lett. 21, 4224–4227 (2011).
  • Matos MJ , VilarS, González-FrancoRMet al. Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: Synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study. Eur. J. Med. Chem. 63, 151–161 (2013).
  • Phansalkar MS , DeshmukhKK, KelkarSLet al. Ind. J. Chem. 26B, 562–563 (1987).
  • Lee JW , ListB. Deracemization of α-aryl hydrocoumarins via catalytic asymmetric protonation of ketene dithioacetals.J. Am. Chem. Soc.134, 18245–18248 (2012).
  • Lipinski CA , LombardoF, DominyBWet al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).
  • Molinspiration Cheminformatics. Nova ulica, Slovakia. www.molinspiration.com/cgi-bin/properties
  • Viña D , MatosMJ, FerinoGet al. 8-substituted-3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation and docking studies. ChemMedChem 7, 464–470 (2012).
  • Binda C , WangJ, PisaniLet al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J. Med. Chem. 50, 5848–5852 (2007).
  • RCSB Protein Data Bank. www.rcsb.org
  • Son SY , MaJ, KondouYet al. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc. Natl Acad. Sci. USA 105, 5739–5744 (2008).
  • Ferino G , CadoniE, MatosMJet al. MAO inhibitory activity of 2-arylbenzofurans versus 3-arylcoumarins: synthesis, in vitro study, and docking calculations. ChemMedChem 8, 956–966 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.